These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

899 related articles for article (PubMed ID: 25548741)

  • 1. Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
    Song BC; Cho YK; Jwa H; Choi EK; Kim HU; Song HJ; Na SY; Boo SJ; Jeong SU
    Clin Mol Hepatol; 2014 Dec; 20(4):355-60. PubMed ID: 25548741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients.
    Chen CH; Lee CM; Hung CH; Wang JH; Hu TH; Changchien CS; Lu SN
    J Gastroenterol Hepatol; 2011 Mar; 26(3):461-8. PubMed ID: 21332543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
    Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
    J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
    Fong TL; Tien A; Jo KJ; Chu D; Cheung E; Mena EA; Phan QQ; Yu AS; Mohammed W; Velasco A; LeDuc VH; Nguyen N; Han SB; Chang M; Bae HS; Cho YW; Tong MJ; Cooper SL
    Dig Dis Sci; 2015 Nov; 60(11):3465-72. PubMed ID: 26138653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors for early HBeAg seroconversion in acute exacerbation of patients with HBeAg-positive chronic hepatitis B.
    Kim HS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    Gastroenterology; 2009 Feb; 136(2):505-12. PubMed ID: 19101558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.
    Cai Q; Chen F; Shao X; Zhang X; Zhao Z; Gao Z
    Antivir Ther; 2015; 20(2):217-24. PubMed ID: 25138110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy.
    Yuen MF; Yuan HJ; Hui CK; Wong DK; Wong WM; Chan AO; Wong BC; Lai CL
    Gut; 2003 Mar; 52(3):416-9. PubMed ID: 12584226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
    Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
    Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.
    Yuen MF; Seto WK; Fung J; Wong DK; Yuen JC; Lai CL
    Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
    Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ
    Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.
    Buster EH; Hansen BE; Lau GK; Piratvisuth T; Zeuzem S; Steyerberg EW; Janssen HL
    Gastroenterology; 2009 Dec; 137(6):2002-9. PubMed ID: 19737568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir.
    Wang CC; Tseng KC; Peng CY; Hsieh TY; Lin CL; Su TH; Tseng TC; Hsu CS; Lin HH; Kao JH
    J Gastroenterol Hepatol; 2013 Jan; 28(1):46-50. PubMed ID: 22989322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage.
    Wu IC; Lai CL; Han SH; Han KH; Gordon SC; Chao YC; Tan CK; Sievert W; Tanwandee T; Xu D; Neo BL; Chang TT
    Hepatology; 2010 Apr; 51(4):1185-9. PubMed ID: 20044806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-year prospective study.
    Lu H; Geng da Y; Shen F; Zhang JY; Lu B; Ma LX
    Virol J; 2011 Sep; 8():444. PubMed ID: 21936898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
    Fung J; Lai CL; Young J; Wong DK; Yuen J; Seto WK; Yuen MF
    Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
    Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B.
    Feld JJ; Ayers M; El-Ashry D; Mazzulli T; Tellier R; Heathcote EJ
    Hepatology; 2007 Oct; 46(4):1057-70. PubMed ID: 17654702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
    Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H
    Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
    Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
    Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.